Centessa Pharmaceuticals Files 8-K

Ticker: CNTA · Form: 8-K · Filed: Jun 17, 2025 · CIK: 1847903

Centessa Pharmaceuticals PLC 8-K Filing Summary
FieldDetail
CompanyCentessa Pharmaceuticals PLC (CNTA)
Form Type8-K
Filed DateJun 17, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: 8-K, regulatory-filing, financial-reporting

TL;DR

Centessa dropped an 8-K on 6/17 for events on 6/16. Standard stuff.

AI Summary

Centessa Pharmaceuticals plc filed an 8-K on June 17, 2025, reporting other events and financial statements as of June 16, 2025. The filing details the company's incorporation in England and Wales and provides contact information for its principal executive offices in Altrincham, Cheshire, United Kingdom.

Why It Matters

This filing serves as an official notification of significant corporate events and financial reporting for Centessa Pharmaceuticals, providing transparency to investors and the market.

Risk Assessment

Risk Level: low — The filing is a routine disclosure and does not appear to contain any immediately alarming or negative information.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing for Centessa Pharmaceuticals?

The primary purpose is to report 'Other Events' and 'Financial Statements and Exhibits' as of June 16, 2025.

When was the earliest event reported in this filing?

The earliest event reported was on June 16, 2025.

Where are Centessa Pharmaceuticals' principal executive offices located?

The principal executive offices are located at 3rd Floor, 1 Ashley Road, Altrincham, Cheshire, WA14 2DT, United Kingdom.

What is Centessa Pharmaceuticals' jurisdiction of incorporation?

Centessa Pharmaceuticals is incorporated in England and Wales.

What is the SEC file number for Centessa Pharmaceuticals?

The SEC file number for Centessa Pharmaceuticals is 001-40445.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on June 17, 2025 regarding Centessa Pharmaceuticals plc (CNTA).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing